Friday, 16 October 2026European Markets

FORFARMERS, MOWI, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - FORFARMERS (FFARM.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
FORFARMERS (FFARM.AS) €2.79 7.21% 5.12%
MOWI (MOWI.OL) kr169.95 4.44% 24.25%
B&S Group (BSGR.AS) €3.94 3.01% 11.82%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. FORFARMERS (FFARM.AS)

7.21% Forward Dividend Yield and 5.12% Return On Equity

ForFarmers N.V. provides feed solutions for conventional and organic livestock farming in the Netherlands, Belgium, Germany, Poland, and the United Kingdom. It offers compound feed and blends, feed for young animals and specialties, raw materials and coproducts, seeds, and fertilizers. The company is involved in production and delivery of feed, as well as engaged in logistics services. ForFarmers N.V. was founded in 1896 and is headquartered in Lochem, the Netherlands.

Earnings Per Share

As for profitability, FORFARMERS has a trailing twelve months EPS of €0.2.

PE Ratio

FORFARMERS has a trailing twelve months price to earnings ratio of 13.95. Meaning, the purchaser of the share is investing €13.95 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.12%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Apr 17, 2023, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 7.21%.

Volume

Today's last reported volume for FORFARMERS is 13788 which is 81.44% below its average volume of 74327.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FORFARMERS's stock is considered to be oversold (<=20).

More news about FORFARMERS.

2. MOWI (MOWI.OL)

4.44% Forward Dividend Yield and 24.25% Return On Equity

Mowi ASA, a seafood company, produces and supplies farmed salmon products worldwide. It operates through three segments: Feed, Farming, and Sales and Marketing. The company is involved in the salmon feed production, salmon farming and primary processing, and seafood secondary processing activities. It offers whole gutted fish, including Label Rouge and organic salmon; and white fish and other seafood products, as well as fillets, steaks, cutlets, portions, loins, kebabs, and steak combos. The company also provides value added products, such as breaded, pre-fried, dusted, marinated, grilled, battered, topped, filled with sauce, delicatessen, fresh fish ready meal, and smoked fish products. It offers its products under the Mowi, Mowi Salmon, Donegal Silver, Admiral's, Pieters, Laschinger, Kritsen, Ducktrap River, Harbour Salmon Co., Rebel Fish, Supreme Salmon, Olav's, Northern Harvest, and Mowi Nutrition brand names. The company was formerly known as Marine Harvest ASA and changed its name to Mowi ASA in December 2018. Mowi ASA was founded in 1964 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, MOWI has a trailing twelve months EPS of kr18.61.

PE Ratio

MOWI has a trailing twelve months price to earnings ratio of 9.13. Meaning, the purchaser of the share is investing kr9.13 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.25%.

More news about MOWI.

3. B&S Group (BSGR.AS)

3.01% Forward Dividend Yield and 11.82% Return On Equity

B&S Group S.A. distributes consumer goods worldwide. The company operates through six segments: B&S Liquors, B&S Beauty, B&S Personal Care, B&S Food, B&S Health, and B&S Retail. The B&S Liquors segment distributes branded liquors to wholesalers, consumers, and e-commerce platforms. The B&S Beauty segment distributes and sells branded fragrances and cosmetics to wholesalers, consumers, and e-commerce platforms. The B&S Personal Care segment distributes and sells branded personal and home care products to retailers. The B&S Food segment distributes a range of branded food and beverages products to duty-free, remote, retail, and maritime markets. The B&S Health segment distributes and sells branded medical products and equipment to maritime and remote markets, pharmacies, and travel clinics. The B&S Retail segment offers consumer electronics and multi-category assortments for consumers at travel locations. The company was founded in 1872 and is based in Betzdorf, Luxembourg.

Earnings Per Share

As for profitability, B&S Group has a trailing twelve months EPS of €0.31.

PE Ratio

B&S Group has a trailing twelve months price to earnings ratio of 12.71. Meaning, the purchaser of the share is investing €12.71 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.82%.

Moving Average

B&S Group's value is above its 50-day moving average of €3.87 and way under its 200-day moving average of €4.48.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 2.15B for the twelve trailing months.

Yearly Top and Bottom Value

B&S Group's stock is valued at €3.94 at 07:30 EST, way under its 52-week high of €5.77 and way higher than its 52-week low of €3.56.

Volume

Today's last reported volume for B&S Group is 982 which is 98.03% below its average volume of 50017.

More news about B&S Group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com